Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

June 27, 2011

Primary Completion Date

June 11, 2013

Study Completion Date

June 11, 2013

Conditions
Clostridium Difficile Infection
Interventions
BIOLOGICAL

VP20621

VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days

BIOLOGICAL

VP20621

VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days

OTHER

Placebo

10 mL placebo once daily for 14 days

BIOLOGICAL

VP20621

VP20621 as oral liquid once daily for 14 days

Trial Locations (59)

Unknown

Modesto

Palm Desert

Sacramento

Aurora

Hartford

Bay Pines

Jacksonville

Honolulu

Chicago

Maywood

Anderson

Lafayette

Lexington

New Orleans

Chevy Chase

Detroit

Grosse Pointe Woods

Novi

Royal Oak

Sault Ste. Marie

Rochester

St Louis

Butte

Omaha

Albany

New York

North Massapequa

Syracuse

The Bronx

Winston-Salem

Akron

Cleveland

Lima

Toledo

Lancaster

West Reading

Memphis

Houston

Temple

Salt Lake City

Winchester

Tacoma

Aalst

Brussels

Leuven

Liège

Calgary

Hamilton

Chicoutimi

Montreal

Trois-Rivières

Cologne

Hanover

Leipzig

Wilhelmshaven

Seville

Barcelona

Majadahonda

Lugano

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY